{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:20:45Z","timestamp":1791001245924,"version":"4.1.0"},"reference-count":60,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013116","name":"Merz Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100013116","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Some studies have shown that incobotulinumtoxinA reduces spasticity-associated pain, but further evidence is needed. This exploratory analysis pooled pain-relief data from six Phase 2 or 3 studies of incobotulinumtoxinA (four placebo-controlled studies) for treating upper limb spasticity in adults. Spasticity-associated pain was assessed at baseline and 4 weeks post incobotulinumtoxinA injection using the disability assessment scale (DAS) for pain. Only data for patients with pain at baseline were analysed. Overall, 544 (incobotulinumtoxinA, N = 415; placebo, N = 129) of 937 patients (58.1%) experienced pain at baseline. At Week 4, a significantly greater proportion of incobotulinumtoxinA- (52.1%) than placebo-treated patients (28.7%; Chi-square p &lt; 0.0001) showed a response (\u22651-point improvement in DAS pain score). In logistic regression analysis, incobotulinumtoxinA-treated patients were 2.6 times more likely to achieve this endpoint than placebo-treated patients. A significant difference between incobotulinumtoxinA and placebo was observed regardless of baseline pain severity. Additionally, 27.1% of incobotulinumtoxinA- versus 12.4% of placebo-treated patients reported complete pain relief at Week 4 (p = 0.0006). Pain relief increased with multiple injection cycles. To achieve patient-centred care, pain relief may be considered a treatment goal in adults with spasticity-associated pain regardless of pain severity. This study contributes to understanding the benefits of incobotulinumtoxinA in treating limb spasticity-associated pain.<\/jats:p>","DOI":"10.3390\/toxins13120887","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T01:29:33Z","timestamp":1639358973000},"page":"887","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6238-3578","authenticated-orcid":false,"given":"J\u00f6rg","family":"Wissel","sequence":"first","affiliation":[{"name":"Department of Neurorehabilitation and Physical Therapy, Vivantes Hospital Spandau, 13585 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Cam\u00f5es-Barbosa","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio de Lisboa Central, 1169-056 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Comes","sequence":"additional","affiliation":[{"name":"Merz Pharmaceuticals GmbH, D-60318 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Althaus","sequence":"additional","affiliation":[{"name":"Merz Pharmaceuticals GmbH, D-60318 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4745-0853","authenticated-orcid":false,"given":"Astrid","family":"Scheschonka","sequence":"additional","affiliation":[{"name":"Merz Pharmaceuticals GmbH, D-60318 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, Department of Neurology, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pmrj.2011.10.001","article-title":"Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity","volume":"4","author":"Doan","year":"2012","journal-title":"PM R"},{"key":"ref_2","first-page":"111","article-title":"Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: A systematic review","volume":"10","author":"Martin","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12955-015-0340-3","article-title":"The negative impact of spasticity on the health-related quality of life of stroke survivors: A longitudinal cohort study","volume":"13","author":"Gillard","year":"2015","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2340\/16501977-0303","article-title":"European consensus table on the use of botulinum toxin type A in adult spasticity","volume":"41","author":"Wissel","year":"2009","journal-title":"J. Rehabil. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1331.2010.03125.x","article-title":"International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments-introduction","volume":"17","author":"Esquenazi","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1615\/CritRevPhysRehabilMed.2013007945","article-title":"A review of spasticity treatments: Pharmacological and interventional approaches","volume":"25","author":"Chang","year":"2013","journal-title":"Crit. Rev. Phys. Rehabil. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"ref_8","unstructured":"Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists in Neurology, and Royal College of Occupational Therapists (2021, March 15). Spasticity in Adults: Management Using Botulinum Toxin. National Guidelines. Available online: https:\/\/www.rcplondon.ac.uk\/guidelines-policy\/spasticity-adults-management-using-botulinum-toxin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3389\/fneur.2021.668370","article-title":"A novel approach to new-onset hemiplegic shoulder pain with decreased range of motion using targeted diagnostic nerve blocks: The ViVe algorithm","volume":"12","author":"Fitterer","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1212\/WNL.0000000000006688","article-title":"High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy","volume":"92","author":"Albrecht","year":"2019","journal-title":"Neurology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2109","DOI":"10.1212\/WNL.0000000000009444","article-title":"Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy","volume":"94","author":"Walter","year":"2020","journal-title":"Neurology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/WNF.0b013e3181b13308","article-title":"Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity","volume":"32","author":"Slawek","year":"2009","journal-title":"Clin. Neuropharm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2340\/16501977-0796","article-title":"Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins.; NT 201) in post-stroke upper limb spasticity","volume":"43","author":"Slawek","year":"2011","journal-title":"J. Rehabil. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/mus.24776","article-title":"Randomized, placebo-controlled trial of incobotulinumtoxinA for upper-limb post-stroke spasticity","volume":"53","author":"Elovic","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1212\/WNL.0000000000003789","article-title":"Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity. The TOWER study","volume":"88","author":"Wissel","year":"2017","journal-title":"Neurology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101376","DOI":"10.1016\/j.rehab.2020.03.005","article-title":"Efficacy of incobotulinumtoxinA for the treatment of adult lower-limb post-stroke spasticity, including pes equinovarus","volume":"64","author":"Bensmail","year":"2020","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12955-020-01304-4","article-title":"Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA","volume":"18","author":"Fheodoroff","year":"2020","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/pmrj.12265","article-title":"IncobotulinumtoxinA treatment in upper-limb post-stroke spasticity in the open-label extension period of PURE: Efficacy in passive function, caregiver burden and quality of life","volume":"12","author":"Marciniak","year":"2020","journal-title":"PM R"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1017\/cjn.2015.321","article-title":"Relationship between botulinum toxin, spasticity, and pain: A survey of patient perception","volume":"43","author":"Shaikh","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpainsymman.2016.01.007","article-title":"OnabotulinumtoxinA improves pain in patients with post-stroke spasticity: Findings from a randomized, double-blind, placebo-controlled trial","volume":"52","author":"Wissel","year":"2016","journal-title":"J. Pain Symptom. Manage."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"jrm00068","DOI":"10.2340\/16501977-2695","article-title":"AbotulinumtoxinA injections in shoulder muscles to improve adult upper limb spasticity: Results from a phase 4 real-world study and a phase 3 open-label trial","volume":"52","author":"Lejeune","year":"2020","journal-title":"J. Rehabil. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0885-3924(00)00146-9","article-title":"Management of spasticity associated pain with botulinum toxin A","volume":"20","author":"Wissel","year":"2000","journal-title":"J. Pain Symptom. Manag."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/PHM.0b013e31824fa9ca","article-title":"Patient registry of outcomes in spasticity care","volume":"91","author":"Esquenazi","year":"2012","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/PHM.0b013e31826ecb02","article-title":"Does botulinum toxin type A decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity? A randomized, double-blind, placebo-controlled trial","volume":"91","author":"Marciniak","year":"2012","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"De Icco, R., Perrotta, A., Berra, E., Allena, M., Alfonsi, E., Tamburin, S., Serrao, M., Sandrini, G., and Tassorelli, C. (2019). Onabotulinum-toxinA reduces temporal pain processing at spinal level in patients with lower limb spasticity. Toxins, 11.","DOI":"10.3390\/toxins11060359"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s10072-005-0379-8","article-title":"Botulinum toxin type A for upper limb spasticity following stroke: An open-label study with individualised, flexible injection regimens","volume":"26","author":"Slawek","year":"2005","journal-title":"Neurol. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1600-0404.2010.01354.x","article-title":"Efficacy and safety of NT 201 for upper limb spasticity of various etiologies\u2014A randomized parallel-group study","volume":"122","author":"Barnes","year":"2010","journal-title":"Acta Neurol. Scand."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1177\/0269215511432016","article-title":"A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor\/invertor overactivity after stroke","volume":"26","author":"Dunne","year":"2012","journal-title":"Clin. Rehabil."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3233\/NRE-141093","article-title":"Onabotulinumtoxin-A injection for disabling lower limb flexion in hemiplegic patients","volume":"35","author":"Rousseaux","year":"2014","journal-title":"NeuroRehabilitation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1474-4422(15)00216-1","article-title":"Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: A double-blind randomised controlled trial","volume":"14","author":"Gracies","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.11336\/jjcrs.8.4","article-title":"Improvement in Disability Assessment Scale after botulinum toxin A treatment for upper limb spasticity","volume":"8","author":"Fujimura","year":"2017","journal-title":"Jpn. J. Compr. Rehabil. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Rosales, R.L., Balcaitiene, J., Berard, H., Maisonobe, P., Goh, K.J., Kumthornthip, W., Mazlam, M., Latif, L.A., Delos Santos, M.M.D., and Chotiyarnwong, C. (2018). Early abobotulinumtoxinA (Dysport\u00ae) in post-stroke adult upper limb spasticity: ONTIME pilot study. Toxins, 10.","DOI":"10.3390\/toxins10070253"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.pmrj.2017.12.006","article-title":"OnabotulinumtoxinA for the treatment of poststroke distal lower limb spasticity: A randomized trial","volume":"10","author":"Wein","year":"2018","journal-title":"PM R"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s00415-020-09777-5","article-title":"Efficacy and safety of incobotulinumtoxinA in post-stroke upper-limb spasticity in Japanese subjects: Results from a randomized, double-blind, placebo-controlled study (J-PURE)","volume":"267","author":"Masakado","year":"2020","journal-title":"J. Neurol."},{"key":"ref_35","first-page":"jrm00028","article-title":"Post hoc analysis of the improvement in shoulder spasticity and safety observed following treatment with incobotulinumtoxinA","volume":"52","author":"Wissel","year":"2020","journal-title":"J. Rehabil. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1177\/0269215513491274","article-title":"The efficacy of botulinum toxin A for spasticity and pain in adults: A systematic review and meta-analysis using the Grades of Recommendation, Assessment, Development and Evaluation approach","volume":"27","author":"Baker","year":"2013","journal-title":"Clin. Rehabil."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"104682","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104682","article-title":"Botulinum toxin type A for upper limb spasticity in poststroke patients: A meta-analysis of randomized controlled trials","volume":"29","author":"Jia","year":"2020","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines:1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"jrm00133","DOI":"10.2340\/16501977-2770","article-title":"Assessing the effectiveness of upper-limb spasticity management using a structured approach to goal-setting and outcome measurement: First cycle results from the ULIS-III Study","volume":"53","author":"Jacinto","year":"2021","journal-title":"J. Rehabil. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"jrm00157","DOI":"10.2340\/16501977-2801","article-title":"Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: Findings from the prospective, observational Upper Limb International Spasticity (ULIS-III) cohort study","volume":"53","author":"Jacinto","year":"2021","journal-title":"J. Rehabil. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.rehab.2019.06.003","article-title":"Botuloscope: 1-year follow-up of upper limb post-stroke spasticity treated with botulinum toxin","volume":"62","author":"Marque","year":"2019","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12955-017-0804-8","article-title":"Initial psychometric validation of the questionnaire on pain caused by spasticity (QPS)","volume":"15","author":"Geister","year":"2017","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1053\/apmr.2002.35474","article-title":"Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb post-stroke spasticity","volume":"83","author":"Brashear","year":"2002","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000375397","article-title":"Post stroke pain: Identification, assessment, and therapy","volume":"39","author":"Harrison","year":"2015","journal-title":"Cerebrovasc. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/practneurol-2013-000536","article-title":"Neuropathic pain: Diagnosis and treatment","volume":"13","author":"Magrinelli","year":"2013","journal-title":"Pract. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.3390\/toxins7072454","article-title":"Botulinum toxin type A for the treatment of neuropathic pain in neuro-rehabilitation","volume":"7","author":"Intiso","year":"2015","journal-title":"Toxins"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Matak, I., B\u00f6lcskei, K., Bach-Rojecky, L., and Helyes, Z. (2019). Mechanisms of botulinum toxin type A action on pain. Toxins, 11.","DOI":"10.3390\/toxins11080459"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: Biology, pharmacology, and toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1254\/jphs.11060FP","article-title":"Inhibition of membrane Na+ channels by A type botulinum toxin at femtomolar concentrations in central and peripheral neurons","volume":"118","author":"Shin","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic pain","volume":"16","author":"Colloca","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40122-018-0100-2","article-title":"A review of chronic musculoskeletal pain: Central and peripheral effects of diclofenac","volume":"7","author":"Atzeni","year":"2018","journal-title":"Pain Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-med-011817-044739","article-title":"Use and misuse of opioids in chronic pain","volume":"69","author":"Volkow","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/AJP.0b013e3182385392","article-title":"Fear-avoidance model of chronic pain: The next generation","volume":"28","author":"Crombez","year":"2012","journal-title":"Clin. J. Pain"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.pain.2013.10.007","article-title":"A multilevel structural equation modeling analysis of vulnerabilities and resilience resources influencing affective adaptation to chronic pain","volume":"155","author":"Sturgeon","year":"2014","journal-title":"Pain"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1097\/j.pain.0000000000001401","article-title":"When pain gets stuck: The evolution of pain chronification and treatment resistance","volume":"159","author":"Borsook","year":"2018","journal-title":"Pain"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4103\/jisprm.jisprm_47_19","article-title":"ULIS (Upper Limb International Spasticity), a 10-year odyssey. An international, multicentric, longitudinal cohort of person-centered spasticity management in real-life practice","volume":"2","author":"Fhedoroff","year":"2019","journal-title":"J. Int. Soc. Phys. Rehabil. Med."},{"key":"ref_57","first-page":"540","article-title":"Preliminary trial of carisoprodol in multiple sclerosis","volume":"192","author":"Ashworth","year":"1964","journal-title":"Practitioner"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ptj\/67.2.206","article-title":"Interrater reliability of a modified Ashworth scale of muscle spasticity","volume":"67","author":"Bohannon","year":"1987","journal-title":"Phys. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12325-018-0833-7","article-title":"IncobotulinumtoxinA efficacy and safety in adults with upper-limb spasticity following stroke: Results from the open-label extension period of a phase 3 study","volume":"36","author":"Marciniak","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa011892","article-title":"Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke","volume":"347","author":"Brashear","year":"2002","journal-title":"N. Engl. J. Med."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/13\/12\/887\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:45:48Z","timestamp":1760168748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/13\/12\/887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,11]]},"references-count":60,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["toxins13120887"],"URL":"https:\/\/doi.org\/10.3390\/toxins13120887","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,11]]}}}